• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Study does not support use of low-dose aspirin after prostate cancer diagnosis

byKathleen W. HigginsandDeepti Shroff Karhade
March 5, 2019
in Cardiology, Chronic Disease, Endocrinology, Public Health, Urology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. This study evaluated the effects of post-diagnosis low-dose aspirin on prostate cancer-specific mortality and found no overall benefit.

2. The study did find a modest benefit in patients taking aspirin for at least 5 years after diagnosis.

Evidence Rating Level: 2 (Good)

Study Rundown: Several recent papers have suggested that regular, low-dose aspirin may improve prostate cancer survival.  However, this has usually been an incidental finding in studies focused on cardiovascular disease prevention, which means that they have lacked appropriate controls.  This study was unique in its focus on patients who took aspirin following a prostate cancer diagnosis, regardless of cardiovascular status.  In general, the authors found no clear reduction in prostate-cancer-specific or all-cause mortality.  However, there was a slight benefit for patients who took aspirin regularly for 5-year or 7.5-years post-diagnosis.  One major limitation was that this study only included aspirin prescriptions and not over-the-counter usage.  However, a 2012 study reported that around 92% of aspirin purchases in Denmark were associated with a prescription, which makes this a reasonable approximation.  However, this assumption would make it difficult to validate these data in other populations, perhaps limiting its applicability.

Click to read the study in Annals of Internal Medicine

Click to read an accompanying editorial in Annals of Internal Medicine

Relevant Reading: Do Aspirin and Other NSAIDs Confer a Survival Benefit in Men Diagnosed with Prostate Cancer? A Pooled Analysis of NIH-AARP and PLCO Cohorts

RELATED REPORTS

#VisualAbstract: Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures

Plant-based diets may be associated with lower risk of aggressive prostate cancer

Wellness Check: Nutrition

In-Depth [retrospective cohort]: This study considered the correlation between post-diagnosis aspirin use and mortality for all Danish men with a new prostate cancer diagnosis between 2000 and 2011. Men were excluded if they were younger than 35, had a previous history of cancer, emigrated, or had chemotherapy within one year of diagnosis (as a proxy for severe disease).  Of note, this study was only possible because of the universal Danish Cancer Registry and National Prescription Registry, and because of the fact that most aspirin in Denmark is dispensed with a prescription.  Among the final population of 29136 patients, around a quarter used low-dose aspirin in the year after their diagnosis.  Of these, around 87% had also used aspirin before their diagnosis.  In the final cohort, 7633 patients died from prostate cancer and 5575 died from other causes.  Following reasonable multivariable adjustment, the hazard ratio for prostate cancer-specific mortality was 0.95 (95% CI, 0.89 to 1.01).  For all-cause mortality, the hazard ratio was 1.12 (CI 1.05 to 1.20).  At the five year timepoint, however, the hazard ratio for prostate cancer-specific mortality was 0.91 (CI 0.83 to 1.01), which fell further by 7.5 years to 0.84 (CI 0.72 to 0.97).  These results do not support the hypothesis that aspirin is beneficial for most patients with newly diagnosed prostate cancer, but there may be a slight benefit after many years.

Image: CC/Wiki

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aspirinprostate cancer
Previous Post

Hypertension in adolescence associated with end-stage renal disease

Next Post

#VisualAbstract: Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease

RelatedReports

#VisualAbstract: Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
StudyGraphics

#VisualAbstract: Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures

February 2, 2023
Vegetarian diet may lower incidence of colorectal cancer
Lifestyle

Plant-based diets may be associated with lower risk of aggressive prostate cancer

January 27, 2023
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Wellness

Wellness Check: Nutrition

January 26, 2023
#VisualAbstract: Thromboprophylaxis with aspirin is non-inferior to low-molecular-weight heparin in preventing death for patients with orthopedic trauma
StudyGraphics

#VisualAbstract: Thromboprophylaxis with aspirin is non-inferior to low-molecular-weight heparin in preventing death for patients with orthopedic trauma

January 24, 2023
Next Post
#VisualAbstract: Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease

#VisualAbstract: Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease

#VisualAbstract: Duration of Initial Empirical Antibiotic Therapy and Outcomes in Very Low Birth Weight Infants

#VisualAbstract: Duration of Initial Empirical Antibiotic Therapy and Outcomes in Very Low Birth Weight Infants

Postextubation administration of high-flow oxygen leads to reduced reintubation and respiratory failure

The PreVent trial: bag-mask ventilation decreases hypoxia in patients undergoing tracheal intubation

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options